Pfizer Inc announced the discontinuation of one of its phase-3 studies based on statistical assessment for futility: the SUN 1107 phase-3 study of Sutent (sunitinib malate) in advanced breast cancer. SUN 1107 evaluated single-agent sunitinib versus single-agent capecitabine for the treatment of a broad range of patients with advanced breast cancer after failure of standard treatment.
The details can be read here.
No comments:
Post a Comment